

Press Release

SYGNIS AG announces global launch of CovCheck™ kit for quality control of the whole genome amplification process

- SYGNIS continues to execute its product launch program 2016
- CovCheck™ ready to use quality control tool for the whole genome amplification (WGA) coverage to determine the quality and integrity of the amplified DNA
- No other product available is able to assess all human chromosomes in a single experiment

Madrid, Spain, and Heidelberg, Germany, October 11, 2016 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced the launch of CovCheck™, a ready to use quality control tool for whole genome amplification (WGA) coverage to determine the quality and integrity of the amplified DNA. The end point PCR based kit, which includes 24 different sets of primer pairs each targeting a specific human chromosome, enables the evaluation of the genomic coverage of four independent single-cell whole genome amplification experiments simultaneously.

CovCheck™ is an end point PCR based kit in a convenient 96-well plate format. No other product available is able to assess all human chromosomes in a single experiment.

Due to its unique and proprietary design CovCheck™ shows a strong correlation between the samples amplified and the real coverage obtained through whole genome sequencing. The product brings the next-generation sequencing (NGS) analysis to a superior level of accuracy and reproducibility and is therefore poised to play a vital role in NGS workflows. CovCheck™ provides a homogenous and comparable approach to determine the quality of the WGA. This will greatly simplify the workflow process and will provide a huge decrease in the costs associated to sequencing samples that do not fulfill the minimum quality standards.

Pilar de la Huerta, Co-CEO and CFO of SYGNIS AG, said: “We are continuously expanding our product portfolio for DNA amplification and sequencing executing on our launching program scheduled for 2016.” **Dr. Heikki Lanckriet, Co-CEO and CSO of SYGNIS AG**, added: “Unbiased DNA amplification and whole genome coverage is one of the most critical aspects within the NGS workflow. With this new tool SYGNIS will provide NGS users with a valuable method to determine the quality and integrity of the amplified DNA, no other product available is able to assess all human chromosomes in a single experiment.”

For further information, please contact:

SYGNIS AG

Pilar de la Huerta
Co-CEO/CFO
Phone: +34 91 192 36 50
Email: pdelahuerta@sygnis.com

MC Services AG

Raimund Gabriel
Managing Partner
Phone: +49 89 210228 30
Email: raimund.gabriel@mc-services.eu



About SYGNIS AG: www.sygnis.com

SYGNIS AG is specialized in the development and the commercialization of proprietary technologies and offers a wide range of different commercial products addressing key challenges in molecular biology. With the acquisition of Expedeon Holdings, Ltd. based in Cambridge, UK, SYGNIS has added a complementary proteomic product portfolio. Resulting from this significant expansion, SYGNIS' product portfolio now covers the entire workflow of molecular biology. The products are sold through a direct sales force and several distribution partners in Europe, the US and Asia. SYGNIS AG has offices in Germany, Spain and the UK, production sites in the UK and the US as well as sales offices in Asia. The company is listed on the German Stock Exchange in Frankfurt in the Prime Standard segment (Ticker: LIO1; ISIN: DE000A1RFM03).

This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason.###